Micromet

Micromet, Inc. is a biopharmaceutical company developing novel proprietary antibodies for the treatment of cancer, inflammation, and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the rest of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in Phase 2 clinical trials for the treatment of patients with acute lymphoblastic leukemia and in Phase 1 clinical trials for the treatment of patients with non-Hodgkin's lymphoma.